Myelodysplastic Syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Dual-Energy Computed Tomography; Procedure: Echocardiography; Drug: Fludarabine; Procedure: Magnetic Resonance Imaging; Drug: Melphalan; Procedure: Multigated Acquisition Scan; Biological: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201; Drug: Tacrolimus; Drug: Thiotepa; Radiation: Total Marrow and Lymphoid Irradiation Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Recruit...
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials

Role of BMP Pathway in MDS Progression
Conditions: Myelodysplastic Syndromes; Acute Myelogenous Leukemia Interventions: Biological: Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care Sponsors: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2023 Category: Research Source Type: clinical trials

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes Interventions: Drug: GLB-001 Sponsors: GluBio Therapeutics Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 24, 2023 Category: Research Source Type: clinical trials

Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome
Conditions: Myelodysplastic Syndromes Interventions: Procedure: Blood test Sponsors: Minovia Therapeutics Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials

Cytokine-induced Memory-like Natural Killer Cell Therapy After Hematopoietic Stem Cell Transplantation for Eradication of Measurable Residual Disease, a Phase I/Ib Clinical Trial
Conditions: Acute Myeloid Leukemia; Leukemia; Leukemia, Myeloid; Myelodysplastic Syndromes; Myeloproliferative Neoplasm; Myeloproliferative Disorders Interventions: Biological: Cytokine Induced Memory-like Natural Killer Cells; Biological: Interleukin-2 Sponsors: Dana-Farber Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials

Interferon- α for TP53 Myeloid Malignancy Post Allo-HSCT
Conditions: Myeloid Leukemia; Myelodysplastic Syndromes Interventions: Drug: IFN- Α Sponsors: Peking University People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Procedure: Biospecimen Collection; Procedure: Chest Computed Tomography; Procedure: Echocardiography; Procedure: Hematopoietic Cell Transplantation; Drug: Methotrexate; Procedure: Multigated Acquisition Scan; Drug: Ruxolitinib Phosphate; Drug: Tacrolimus Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Conditions: Myelodysplastic Syndromes Interventions: Drug: Luspatercept Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS
Conditions: Myelodysplastic Syndromes Interventions: Biological: Unrelated Umbilical Cord Blood; Drug: Venetoclax; Drug: Decetabine; Drug: Azacitidine Sponsors: Anhui Provincial Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials

CyFluATG in Lower Risk MDS
Conditions: Myelodysplastic Syndromes Interventions: Drug: cyclophosphamide, fludarabine, and antithymocyte globulin Sponsors: Asan Medical Center Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
Conditions: Myelodysplastic Syndromes Interventions: Drug: IV Decitabine; Drug: Decitabine and cedazuridine; Drug: only Decitabine and cedazuridine Sponsors: Otsuka Beijing Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Conditions: Myelodysplastic Syndrome; Beta Thalassemia Interventions: Drug: Luspatercept Sponsors: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials

Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide
Conditions: Multiple Myeloma; Myelodysplastic Syndromes; Lymphoma Sponsors: Qianfoshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Conditions: Clonal Cytopenia of Undetermined Significance; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelofibrosis; Polycythemia Vera Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Dietary Supplement: Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement; Dietary Supplement: Piperine Extract (Standardized); Drug: Placebo Administration; Other: Questionnaire Administration Sponsors: University of Southern California; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Hodgkin Lymphoma; Myelodysplastic Syndrome; Myelofibrosis; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Procedure: Biospecimen Collection; Drug: Granulocyte Colony-Stimulating Factor; Drug: Hematopoietic Cell Transplantation Conditioning Regimen; Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine; Procedure: Pheresis; Drug: Placebo Administration; ...
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials